Fatty acid profile and affective dysregulation in irritable bowel syndrome

Kilkens, Tessa; Honig, Adriaan; Maes, Michaël; Lousberg, Richel; Brummer, Robert Jan

doi:10.1007/s11745-004-1247-x

Cited by 14 publications

(16 citation statements)

References 57 publications

Supporting

Mentioning

Contrasting

Unclassified

Order By: Relevance

“…However, there is only limited data on plasma PUFA composition in subjects with IBS. One previous study reported that the plasma PUFA composition of 23 patients with IBS did not differ from controls [13], while another found that both plasma arachidonic acid and total n-3 PUFA concentrations were elevated in a cohort of 41 patients with IBS compared to controls [14]. By contrast, we hypothesized that subjects with IBS might have disturbed intestinal absorption of fatty acids, as reflected in their serum composition of PUFA.…”

Section: Introductionmentioning

confidence: 76%

Serum fatty acid profile in subjects with irritable bowel syndrome

Solakivi

Kaukinen

Kunnas

et al. 2010

Scandinavian Journal of Gastroenterology

View full text Add to dashboard Cite

show abstract

Section: Introductionmentioning

confidence: 76%

Serum fatty acid profile in subjects with irritable bowel syndrome

Solakivi

Kaukinen

Kunnas

et al. 2010

Scandinavian Journal of Gastroenterology

View full text Add to dashboard Cite

show abstract

“…Although a further analysis according to disease subtype (C-IBS, A-IBS, or D-IBS) did not yield any statistically signifi cant results, there appeared to be a uniform increase across all disease subtypes. Interestingly, a previous study that examined plasma fatty acid profi les in a mixed gender IBS cohort did not report any alterations ( 27 ). However, although that study did report AA concentrations, it was not one of its statistical endpoint measures nor did it examine the infl ammatory mediators produced along the AA cascade.…”

Section: Downloaded Frommentioning

confidence: 95%

“…Elevated IL-6 levels have, to date, represented one of the most robust fi ndings supportive of immune activation in IBS ( 11,25,26 ). Despite the importance of the AA cascade, the limited data available on PUFA in IBS have not focused on either the parent molecule or the immunomodulatory metabolites produced along the pathway ( 27 ).…”

Section: Fatty Acid Analysismentioning

confidence: 99%

Marked elevations in pro-inflammatory polyunsaturated fatty acid metabolites in females with irritable bowel syndrome

Clarke

Fitzgerald

Hennessy

et al. 2010

Journal of Lipid Research

View full text Add to dashboard Cite

Irritable bowel syndrome (IBS) is a common and potentially disabling, though nonfatal, medical disorder that can affect up to 20% of the population. It is the most common functional gastrointestinal disorder referred to gastroenterologists ( 1 ). Although it has evolved over the years in terms of nomenclature ( 2, 3 ), classifi cation ( 4-6 ), and appreciation of its frequency ( 7 ), a poor understanding of disease pathophysiology has remained a constant. According to the Rome III criteria, a symptom-based classifi cation system, the disease-defi ning symptom profi le encompasses abdominal pain and an altered bowel habit, with distension, bloating, and a variety of disturbances in defecatory function being additional features ( 8 ).The disorder is increasingly viewed as a disorder of the brain-gut axis, a construct describing a bidirectional interaction between the gastrointestinal tract (GIT), incorporating the intestinal epithelial barrier, the mucosa-associated lymphoid tissue (MALT), gut muscle and the enteric nervous system (ENS), and the central nervous system (CNS) ( 9, 10 ). Most recently, the proposal that low-grade infl ammation, as evidenced by the release of mast cell mediators and activation of lymphocytes in the colo-rectal mucosa and by the detection of elevated levels of pro-infl ammatory cytokines in serum ( 8,(11)(12)(13), has provided a new dimension to this paradigm. The source of this low-grade infl ammation, or immune activation, whether luminal or central, has remained elusive. Polyunsaturated fatty acids (PUFA) and their metabolites have been shown to infl uence infl ammatory processes ( 14 ). Moreover, a pro-infl ammatory PUFA profi le has recently been reported in the maternal separation rodent model, an animal model of IBS ( 15 ).Abstract Irritable bowel syndrome (IBS) is the most common functional gastrointestinal disorder referred to gastroenterologists. Although the pathophysiology remains unclear, accumulating evidence points to the presence of low-level immune activation both in the gut and systemically. Circulating polyunsaturated fatty acids (PUFA) have recently attracted attention as being altered in a variety of disease states. Arachidonic acid (AA), in particular, has been implicated in the development of a pro-infl ammatory profi le in a number of immune-related disorders. AA is the precursor of a number of important immunomodulatory eicosanoids, including prostaglandin E 2 (PGE 2 ) and leukotriene B 4 (LTB 4 ). We investigated the hypothesis that elevated plasma AA concentrations in plasma contribute to the proposed pro-infl ammatory profi le in IBS. Plasma AA and related PUFA were quantifi ed by gas chromatography analysis in IBS patients and controls. Both PGE 2 and LTB 4 were measured in serum using commercially available ELISA assays. AA concentrations were elevated in our patient cohort compared with healthy controls. Moreover, we demonstrated that this disturbance in plasma AA concentrations leads to downstream elevations in eicosanoids. Together, our data identifi es...

show abstract

“…The level of depression was assessed using the Beck Depression Inventory (BDI-II), which is used frequently in the evaluation of depression in gastrointestinal pathologies [17][18][19]. It contains 21 multiple-choice items, each with a score from 0 to 3, so that the total point score varies from 0 to 63.…”

Section: Psychometric Evaluationmentioning

confidence: 99%